ReviewPharmacy (Basel, Switzerland)2023
Pharmacovigilance in High-Income Countries: Current Developments and a Review of Literature.
Review in Pharmacy (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Global burden and socioeconomic correlates of drug use disorders in women of childbearing age: insights from GBD and NHANES.European archives of psychiatry and clinical neuroscience · 2026Article
- Prevalence, Patterns, and Factors Associated With Adverse Drug Reactions Among People Living With HIV Receiving Antiretroviral Therapy at a Secondary Healthcare Facility in Ghana: A Retrospective Cross-Sectional Study.Health science reports · 2026Article
- Global Pharmaceutical Regulation: Comparative Frameworks and Operations.Pharmacy (Basel, Switzerland) · 2026Review
- Medication-related nephrotic syndrome: a real-world study from 2004 to 2024 based on the Food and Drug Administration Adverse Event Reporting System.Therapeutic advances in drug safety · 2026Article
- Global pharmacovigilance reporting: comparative analysis of adverse event obligations across five major regulatory authorities.Frontiers in drug safety and regulation · 2026Article
- Framework for identifying reference countries in drug safety evaluation: an application of the analytic hierarchy process.Journal of pharmaceutical policy and practice · 2026Article
- Metabolic and Endocrine ADRs of Atypical Antipsychotics (AAPs) in Paediatric Patients with Autism Spectrum Disorder (ASD): A Review of Prevalence, Risk Factors, and Implications for Clinical Monitoring.Journal of clinical medicine · 2025Review
- Aioli: Standardising Drugs in the FDA Adverse Event Reporting System (FAERS) to RxNorm and Anatomical Therapeutic Chemical (ATC) Codes.Pharmacoepidemiology and drug safety · 2025Article
- Assessment of Pharmacovigilance Across University Hospitals in Morocco.Drug safety · 2025Article
- Assessment of public awareness and perspectives towards adverse drug reaction reporting system in Karachi, Pakistan.PloS one · 2025Article
- Pharmacovigilance - Technological Advancements, Recent Developments and Innovations.Current drug safety · 2025Review
- Descriptive analysis of the national drug adverse events (AEs) database in Lebanon.Journal of pharmaceutical policy and practice · 2025Article
- Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries.Therapeutic advances in drug safety · 2025Article
- The safety of herbal medicines in low- and middle-income countries (LMICs): current landscape and promoting the pharmacovigilance practices.Journal of pharmaceutical policy and practice · 2025Article
- Constructing an evaluation framework for primary pharmacovigilance systems in developing countries: a case study from China.Frontiers in pharmacology · 2025Article
- Part 1 - imidazolines and the changing face of nasal decongestants.Frontiers in pharmacology · 2025Review
- Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals.Pharmacy (Basel, Switzerland) · 2024Article
- Ensuring safe and effective pharmacotherapy: The role of "community pharmacology" in attaining "health for all" from the Indian perspective.Journal of family medicine and primary care · 2024Article
- Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity.iScience · 2024Article
- The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System.Drug safety · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world bank has classified 80 economies based on their Gross National Income (GNI) per capita as High-Income. European Medicines Agency (EMA), Food and Drug Administration (FDA), and Pharmaceuticals and Medical Devices Agency (PMDA) are the major regulatory stakeholders driving global pharmacovigilance regulations. The purpose of this article is to describe pharmacovigilance systems and processes in high-income countries, particularly those that are also members of the International Conference on Harmonization (ICH). All high-income countries are members of the WHO PIDM. The income level of a country has a direct relationship with medicine safety measures. All ten pioneering members of the Uppsala monitoring centre are from high-income countries and were the first responders after the thalidomide tragedy by making drug evaluation committees, introducing the ADR reporting forms and taking safety measures. Despite access to the VigiBase, some countries have separate databases for managing and analyzing data like Canada Vigilance online database, FDA Adverse Event Reporting System, the French pharmacovigilance database and European Union's system Eudravigilance. All high-income countries have robust pharmacovigilance systems. USFDA and EMA are the world leaders in the field of pharmacovigilance. Most high-income countries follow EMA guidelines. Medicine safety is directly influenced by a country's income level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.